Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01721967 · ClinicalTrials.gov registry record · Phase 4
Ranolazine for the Treatment of Chest Pain in HCM Patients
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT01721967 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 14 participants.
The verdict
NCT01721967, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of RHYME is to evaluate the safety and efficacy of ranolazine in Hypertrophic Cardiomypathy patients with chest pain or dyspnea despite treatment with standard medical therapy. This is a small, pilot, open-label (non-randomized) study of an approved drug for the treatment of angina in a novel patient population (adult patient population with hypertrophic cardiomyopathy).
Interventions
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01721967
The ClinicalTrials.gov registry entry for NCT01721967 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranolazine is the first listed.
NCT01721967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01721967 about?
NCT01721967 is a clinical study titled "Ranolazine for the Treatment of Chest Pain in HCM Patients". The purpose of RHYME is to evaluate the safety and efficacy of ranolazine in Hypertrophic Cardiomypathy patients with chest pain or dyspnea despite treatment with standard medical therapy. This is a small, pilot, open-label (non-randomized) study of an approved drug for the treatment of angina in a ...
What is the current status of trial NCT01721967?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2012-11. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01721967?
The interventions under investigation include: Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01721967?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.